The surgical robot developer will use the series B financing, co-led by SinoPharm, to support it through its application for market clearance.

NTT, Symantec and FireEye all contributed to the $25m round for ShieldX, which previously raised $9m in its 2015 series A round.

NEA has led a series B round for cancer treatment developer Pionyr Immunotherapeutics, co-founded by researchers from UC San Francisco and University of Toronto.

The ocular biotech spinout was has received cash from backers including the VTC Innovation Fund as it prepares to take its dry eye syndrome treatment through clinical testing.

The Renren-backed financial services provider, which gives 10% of its fees to charitable schemes, has now raised $67m altogether.

Hand sanitation monitoring system provider SwipeSense has secured $10.6m to expand its team and accelerate product development.

Samsung and ABB have contributed to a $20m round for smart vision product developer Vion Technology, which will use the cash for hiring and product development.

Alexandria Venture Investments has participated in an NEA-led round that took the total raised by the metabolic disease drug startup to $60m.

The crop additive developer has secured $12.3m for product development and commercialisation from a consortium led by Syngenta.